BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Helena Shifrin, Odelia Mouhadeb, Nathan Gluck, Chen Varol, Marta Weinstock. Cholinergic Anti-Inflammatory Pathway Does Not Contribute to Prevention of Ulcerative Colitis by Novel Indoline CarbamatesJournal of Neuroimmune Pharmacology 2017; 12(3): 484 doi: 10.1007/s11481-017-9735-8
2
S. N. Hong, H. J. Kim, K. H. Kim, S.-J. Han, I. M. Ahn, H. S. Ahn. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South KoreaAlimentary Pharmacology & Therapeutics 2017; 45(2): 253 doi: 10.1111/apt.13851
3
Dong Il Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S. Puri, Suk-Kyun Yang. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessmentIntestinal Research 2018; 16(1): 4 doi: 10.5217/ir.2018.16.1.4
4
Diana Castillo-Martínez, Luis M. Amezcua-Castillo, Julio Granados, Carlos Pineda, Luis M. Amezcua-Guerra. Is Takayasu arteritis the result of a Mycobacterium tuberculosis infection? The use of TNF inhibitors may be the proof-of-concept to demonstrate that this association is epiphenomenalClinical Rheumatology 2020; 39(6): 2003 doi: 10.1007/s10067-020-05045-z
5
Yu Zhou, Juan Du, Hong-Yan Hou, Yan-Fang Lu, Jing Yu, Li-Yan Mao, Feng Wang, Zi-Yong Sun. Application of ImmunoScore Model for the Differentiation between Active Tuberculosis and Latent Tuberculosis Infection as Well as Monitoring Anti-tuberculosis TherapyFrontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00457
6
Ying Zhou, Chun-yan Tan, Zhi-jiang Mo, Qi-le Gao, Dan He, Jiong Li, Rong-fu Huang, Yan-bing Li, Chao-feng Guo, Qiang Guo, Long-jie Wang, Guan-teng Yang, Hong-qi Zhang. Polymorphisms in the SP110 and TNF-α Gene and Susceptibility to Pulmonary and Spinal Tuberculosis among Southern Chinese PopulationDisease Markers 2017; 2017: 1 doi: 10.1155/2017/4590235
7
Ashish Agarwal, Saurabh Kedia, Saransh Jain, Vipin Gupta, Sawan Bopanna, Dawesh P Yadav, Sandeep Goyal, Venigalla Pratap Mouli, Rajan Dhingra, Govind Makharia, Vineet Ahuja. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in IndiaIntestinal Research 2018; 16(4): 588 doi: 10.5217/ir.2018.00023
8
Hanif Esmail, Robert J. Wilkinson. Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF TherapyAnnals of the American Thoracic Society 2017; 14(5): 621 doi: 10.1513/AnnalsATS.201701-055ED
9
Ibrahim Abubakar, Ajit Lalvani, Jo Southern, Alice Sitch, Charlotte Jackson, Oluchukwu Onyimadu, Marc Lipman, Jonathan J Deeks, Chris Griffiths, Graham Bothamley, Onn Min Kon, Andrew Hayward, Joanne Lord, Francis Drobniewski. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test studyHealth Technology Assessment 2018; 22(56): 1 doi: 10.3310/hta22560
10
Jae Hee Cheon. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel diseaseJournal of Gastroenterology and Hepatology 2017; 32(4): 769 doi: 10.1111/jgh.13612
11
Jason K. Hou, Jennifer R. Kramer, Peter Richardson, Shubhada Sansgiry, Hashem B. El-Serag. Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha AntagonistsInflammatory Bowel Diseases 2017; 23(2): 254 doi: 10.1097/MIB.0000000000001003
12
V.B. Pereira, V.P. da Cunha, T.M. Preisser, B.M. Souza, M.Z. Turk, C.P. De Castro, M.S.P. Azevedo, A. Miyoshi. Lactococcus lactiscarrying a DNA vaccine coding for theESAT-6antigen increases IL-17 cytokine secretion and boosts the BCG vaccine immune responseJournal of Applied Microbiology 2017; 122(6): 1657 doi: 10.1111/jam.13449
13
Saurabh Kedia, Venigalla Pratap Mouli, Nagesh Kamat, Jeeva Sankar, Ashwin Ananthakrishnan, Govind Makharia, Vineet Ahuja. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of TuberculosisThe American Journal of Gastroenterology 2020; 115(3): 340 doi: 10.14309/ajg.0000000000000527
14
Dong II Park, Tadakazu Hisamatsu, Minhu Chen, Siew Chien Ng, Choon Jin Ooi, Shu Chen Wei, Rupa Banerjee, Ida Normiha Hilmi, Yoon Tae Jeen, Dong Soo Han, Hyo Jong Kim, Zhihua Ran, Kaichun Wu, Jiaming Qian, Pin-Jin Hu, Katsuyoshi Matsuoka, Akira Andoh, Yasuo Suzuki, Kentaro Sugano, Mamoru Watanabe, Toshifumi Hibi, Amarender S Puri, Suk-Kyun Yang. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessmentJournal of Gastroenterology and Hepatology 2018; 33(1): 20 doi: 10.1111/jgh.14019
15
Jun Tomio, Hayato Yamana, Hiroki Matsui, Hiroyuki Yamashita, Takashi Yoshiyama, Hideo Yasunaga. Tuberculosis screening prior to anti‐tumor necrosis factor therapy among patients with immune‐mediated inflammatory diseases in Japan: a longitudinal study using a large‐scale health insurance claims databaseInternational Journal of Rheumatic Diseases 2017; 20(11): 1674 doi: 10.1111/1756-185X.13190
16
Aye Aye Thi, Aula Abbara, Sonia Bouri, Simon M Collin, Paul Wolfson, Leah Owen, Kevin G Buell, Laurence John, Ailsa L Hart. Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort studyFrontline Gastroenterology 2018; 9(3): 234 doi: 10.1136/flgastro-2017-100951
17
Hsiang-Chun Lai, Chia-Hsi Chang, Ken-Sheng Cheng, Tsung-Wei Chen, Yuan-Yao Tsai, Jen-Wei Chou. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in TaiwanGastroenterology Research and Practice 2019; 2019: 1 doi: 10.1155/2019/7132875
18
Michael Kwan-Lung Ko, Siew C Ng, Lung-Yi Mak, Michael K Li, Fu Hang Lo, Carmen Ka Man Ng, Wai Cheung Lao, Steve Tsang, Kam Hon Chan, Yee Tak Hui, Edwin Hok Shing Shan, Ching Kong Loo, Aric J Hui, Wai Pan To, Ivan F Hung, Wai K Leung. Infection-related hospitalizations in the first year after inflammatory bowel disease diagnosisJournal of Digestive Diseases 2016; 17(9): 610 doi: 10.1111/1751-2980.12397
19
Jang Wook Lee, Chang Hwan Choi, Ji Hoon Park, Jeong Wook Kim, Sang Bum Kang, Ja Seol Koo, Young-Ho Kim, You Sun Kim, Young Eun Joo, Sae Kyung Chang. Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel diseaseIntestinal Research 2016; 14(2): 146 doi: 10.5217/ir.2016.14.2.146
20
Guilherme P Ramos, Gregory Stroh, Badr Al-Bawardy, William A Faubion, Konstantinos A Papadakis, Patricio Escalante. Outcomes of Treatment for Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease Receiving Biologic TherapyInflammatory Bowel Diseases 2018; 24(10): 2272 doi: 10.1093/ibd/izy133
21
Jungsil Lee, Eunyoung Kim, Eun Jin Jang, Chang-Hoon Lee, Eun Young Lee, Jong Pil Im, Sung Koo Han, Jae-Joon Yim. Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor AntagonistAnnals of the American Thoracic Society 2017; 14(5): 690 doi: 10.1513/AnnalsATS.201608-647OC